Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Rgd-containing cyclic peptides

a technology of cyclic peptides and peptides, which is applied in the direction of peptides, peptide/protein ingredients, immunoglobulins, etc., can solve the problem of limited number of peptides that can be simultaneously tested in the “spatial screening” process, and achieve the effect of inhibiting the activity of v3 integrin

Inactive Publication Date: 2016-01-21
RGT UNIV OF CALIFORNIA
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent is about a group of compounds that can inhibit a protein called αvβ3 integrin. The compounds have a specific formula and contain specific amino acids. These compounds can be used to make a pharmaceutical composition and are effective at treating diseases that result from overactivity of αvβ3 integrin. The invention also includes a method for inhibiting αvβ3 integrin using the compounds.

Problems solved by technology

However, due to intrinsic constraints of these screening processes, only L-amino acid residues can be included in the phage display peptide libraries and the number of peptides that can be simultaneously tested in the “spatial screening” process is rather limited.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Rgd-containing cyclic peptides
  • Rgd-containing cyclic peptides
  • Rgd-containing cyclic peptides

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of 8Mer Library 1

[0116]Library 1 was prepared according to the scheme shown in FIG. 2. TentaGel resin (2 g, loading: 0.27 mmole / g) was swollen in DMF for 4 h. After filtration, a solution of Fmoc-D-Cys(Trt)-OH (948.83 mg, 1.62 mmole), HOBt (218.7 mg, 1.62 mmole) and DIC (250.85 μL, 1.62 mmole) was added to the beads. The coupling reaction was carried out at room temperature for 2 h. After filtration, the beads were washed three times each with DMF, MeOH and DMF. The beads were subjected to Fmoc deprotection with 20% 4-methyl piperieine (5 min, 15 min). After washing with DMF, MeOH and DMF, the beads were split into 19 columns and respectively coupled with 19 natural D amino acid (See Table 3) in a similar manner described above. According to the standard “split-mix” approach, the library was completed. The beads were then dried under vacuum for overnight before adding a TFA-based cleavage cocktail (TFA: phenol: water: thioanisole: Tis, 10:0.5:0.5:0.5:0.25, v / w / v / v / v) for...

example 2

Preparation of 9Mer Library 2

[0117]The same synthetic route and amino acids used in the synthesis of library 1, were employed with the exception of an additional amino acid added at x8 position to create a 9mer.

example 3

Preparation of 8Mer Library 3

[0118]Library 3 was prepared according to the scheme shown in FIG. 10. TentaGel resin (2 g, loading: 0.27 mmole / g) was swollen in water for 24 h. After filtration, a solution of Fmoc-OSu (7.29 mg, 0.0216 mmole), Alloc-OSu (17.2 mg, 0.0864 mmole) and DIPEA (37.60 μL, 0.216 mmole) in DCM / diethyl ether (110 mL: 90 mL) was added to the beads, and the reaction was allowed to occur under vigorously shaking for 30 min. Then the inner layer of the beads was protected by treatment with (Boc)2O (589.30 mg, 2.7 mmole) / DIPEA (940.4 μL, 5.4 mmole) for 2 h. After Alloc deprotection, a solution of Ac-Gly-OH (101.12 mg, 0.864 mmole), HOBt (117 mg, 0.864 mmole) and DIC (128.3 μL, 0.864 mmole) in DMF was used to block the exposed N-terminus on the bead surface. Upon Fmoc deprotection and Boc deprotection, the library was synthesized under the same condition as library 1, following the standard “split-and-mix” approach. The beads were then dried under vacuum overnight befo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention is drawn to cyclic RGD peptides linked via a disulfide bond, where the terminal cysteines are preferably in the D configuration. These peptides target αvβ3 integrin on tumor cells and neovasculatures and function as targeting agents for tumor diagnostic imaging and therapy. Compared with the commonly used RGD ligands, compounds of the present invention have improved targeting efficacy and lower nonspecific binding to normal organs. Moreover, the compounds of the present invention can be functionalized to conjugate imaging payload without decreasing binding strength.

Description

CROSS-REFERENCES TO RELATED APPLICATIONS[0001]This application claims priority to U.S. Provisional Application No. 61 / 288,585, filed Dec. 21, 2009, which is incorporated in its entirety herein for all purposes.STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT[0002]This invention was made with Government support under Grant Nos. CA115483 and CA135345, awarded by the National Institutes of Health. The Government has certain rights in this invention.BACKGROUND OF THE INVENTION[0003]αvβ3 integrin serves as a receptor for a variety of extracellular matrix proteins displaying the arginine-glycine-aspartic acid (RGD) tripeptide sequence. These proteins include vitronectin, fibronectin, fibrinogen, laminin, collagen, Von Willibrand's factor, osteoponin, and adenovirus particles (Jin, H. and J. Varner, Br. J Cancer, 2004. 90(3): p. 561-5). αvβ3 integrin, expressed on the surface of various normal and cancer cell types, is involved in multiple physio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K7/54
CPCA61K38/00C07K7/54C07K14/78C07K7/64
Inventor LAM, KIT S.WANG, YANXIAO, WENWU
Owner RGT UNIV OF CALIFORNIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com